Welcome to the latest edition of the  BioLines  Weekender. 

Policy, programming and telling the industry story are front and center these days as well as creating new benefits for Members. The Team has been busy on all of these fronts as we help our Members as they help Patients.

Over the last two weeks, the BioNJ Team...
  • Hosted a successful Third Annual Beyond Value Frameworks: Defining the Value of Medical Innovation Workshop which brought together multi-stakeholders for an open discussion on how to become more influential regarding framework decisions to ensure Patients have access to the right medications at the right time...every time
  • Finalized details for next Thursday's C-Suite Summit which will bring together more than 200 industry professionals to discuss "Healthcare and Biopharma in Transformation: Industry's New Edge of Opportunity" (Click here to register.)
  • Opened registration for BioNJ's Third Annual Patient Advocacy Summit on December 13; free to Patient advocacy groups and BioNJ Innovation Members
  • Began planning BioNJ's 2019 BioPartnering Conference with our partner J.P. Morgan
  • Met with a number of legislators in Trenton to discuss opportunities to support the life sciences industry
  • Spoke with two companies interested in locating in New Jersey
  • Participated in the New Jersey State Chamber, Opportunity NJ and Student2Science's Board Meetings
  • Announced a Members-only  Health Benefits Planproviding high-quality, affordable group health benefits to BioNJ Member companies and their employees
We hope to see you next Thursday at BioNJ's C-Suite Summit where you'll hear from  FDA, Novartis, Novo Nordisk,  Celgene, Alnylam, Microsoft, Google and more!   Click here for the agenda.

Because Patients Can't Wait®,
The BioNJ Team
BioNJ Calendar

BioNJ's C-Suite Summit
Bridgewater Marriott, Bridgewater, NJ

October 25, 2018
BioNJ's Patient Advocacy Summit
Celgene Corporation, 179 Passaic Ave, Summit, NJ

December 13, 2018
Inspiring Women in STEM Conference
Sanofi , Bridgewater, NJ

December 7, 2018

Putting Patients First: The Value of Medical Innovation
Brought to You by Celgene Corporation

Medical innovation enables longer and better quality lives and, in turn, reduces the costs of healthcare. Share with our community how your medical innovation is improving lives and impacting healthcare costs. Send us your Patient and related stories to BioNJ@BioNJ.org. Plus, click here for valuable tools and resources on the Value of Medical Innovation.

Gov. Phil Murphy signed an  executive order to establish the Future of Work Task Force.  The task force, which was previewed in Murphy's Economic Development Strategic Plan, will study how technology innovation will impact the development of jobs in New Jersey. 
The task force will be chaired by Dr. Beth Simone Noveck, New Jersey's Chief Innovation Officer.  "Building a stronger and fairer economy requires a laser focus on reclaiming New Jersey as the state of innovation," Murphy said. 

At 6:21 p.m., the sun was beginning to set in New York City, and Eric Gelber started his final lap around Central Park. A crowd of supporters were running with him and cheering him on, and cowbells were ringing along the race course. Every step was painful. When he finally crossed the finish line, he broke down and kissed and hugged his wife. He had just run 200 miles and raised over $320,000-bringing his lifetime fundraising total to more than $1.1 million and moving us one step closer to a cure for  multiple myeloma .

A survey from the Multiple Sclerosis Association of America (MSAA), sponsored by Celgene, showed people with multiple sclerosis are worried about brain volume loss and want more information.

BioNJ in the News

BioNJ to Offer One of the First Industry Health Plan Solutions in America
BioNJ and the Affiliated Physicians and Employers Master Trust ("APEMT") announced that they have reached a definitive agreement to allow BioNJ to become a sponsor in the APEMT Health Plan to benefit member companies of BioNJ. The new partnership will enable BioNJ to provide high-quality, affordable group health benefits to its member companies and their employees. The BioNJ sponsorship in the APEMT is subject to state regulatory approval and is expected to be operational as of January 1, 2019. APEMT Health Plan is an existing Self-Insured Multiple Employer Welfare Arrangement ("MEWA") registered with the New Jersey Department of Banking and Insurance as well as the New Jersey Department of Labor and Workforce Development which provides coverage to members of participating Associations throughout New Jersey.

William Hait, global head, external innovation,  Johnson & Johnson, has been named the 2019 Dr. Sol J. Barer Award winner for Vision, Innovation and Leadership by  BioNJThe award, named for the founder and former chairman and CEO of  Celgene Corp. , recognizes outstanding research and business leaders who have made significant contributions to the growth and prosperity of the life sciences industry in New Jersey and throughout the world.

NJ Company News

Ever proud of our ecosystem, we are pleased to share our New Jersey Company News. Be sure to click on the article titles below to read the full release.

Jersey City-based BioNJ Member   SCYNEXIS, Inc. announced the dosing of the first patient with a  Candida auris  infection, an emerging life-threatening and multidrug-resistant fungal pathogen, in a Phase 3 open-label study evaluating oral ibrexafungerp (formerly SCY-078) in patients with candidiasis caused by C. auris  (the CARES Study). Ibrexafungerp, the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, is in clinical development for the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis (IC), invasive aspergillosis (IA) and refractory invasive fungal infections.

Princeton-based BioNJ Member Ophthotech Corporation announced completion of patient recruitment for its Phase 2b clinical trial of Zimura® (avacincaptad pegol), the Company's complement factor C5 inhibitor, monotherapy in patients with geographic atrophy secondary to dry age-related macular degeneration (AMD). Complement factor C5 is a central component of the complement cascade and is believed to be involved in the development and progression of AMD.

In mid-November 2017, the U.S. Food and Drug Administration (FDA) approved what is perhaps the boldest use of digital technology in healthcare: a pill -- developed by Princeton-based BioNJ Member Otsuka Pharmaceutical Co., Ltd. -- that is integrated with an ingestible sensor that captures information about whether the patient has complied with her medication regimen. A patient ingests the pill and it sends the data to a patch worn on her torso, which adds various physiologic measures. 

Princeton-based BioNJ Member Otsuka Pharmaceutical Co., Ltd. and Proteus Digital Health (Proteus) announce the signing of an expanded global collaboration agreement that will strengthen the relationship between the two companies for the further development and commercialization of a portfolio of medicines including the ABILIFY MYCITE® (aripiprazole tablets with sensor) offering, which received NDA approval from the U.S. Food and Drug Administration in November 2017. 

Pennington-based BioNJ Member  OncoSec Medical Incorporated announced that Dr.  Alain Algazi , Associate Professor of Medicine at UCSF, will present data from OncoSec's OMS-100 study of TAVO (intratumoral tavokinogene telseplasmid) as a monotherapy treatment for metastatic melanoma during the Melanoma Bridge Conference The presentation will describe the OMS-100 Phase 2 multicenter, single-group study which evaluated the efficacy and safety observed after repeat dosing and different intervals between TAVO cycles. 

Company President and CEO of Pennington-based BioNJ Member  OncoSec Immunotherapies , Dan O'Connor, discussed the company's late-stage studies to treat and potentially cure advanced melanoma and triple negative breast cancers. Their technology turns cold tumors hot which then allows combo therapy to attack and destroy cancer cells from inside the body. Early bench studies show very positive results.

Positive results from a feasibility study investigating Princeton-based BioNJ Member Photocure's Hexvix® with flexible cystoscopy in the outpatient (office) setting have been published in Research and Reports in Urology . The investigators concluded that routine outpatient management of patients with Blue Light Cystoscopy (BLC™) with a flexible scope for early identification of recurrent lesions using on-site biopsy, is feasible in patients with non-muscle invasive bladder cancer (NMIBC). 

Two pivotal Phase 3 placebo-controlled trials evaluating Bridgewater-based BioNJ Member Sanofi's Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps ("CRSwNP") met all primary and secondary endpoints. CRSwNP is a chronic disease in which Type 2 or allergic inflammation causes polyps that obstruct the sinus and nasal passages, leading to severe congestion, nasal discharge, facial pain or pressure, and reduced sense of smell and taste. 

Princeton-based BioNJ Member  Agile Therapeutics, Inc.  announced that it has received a response from FDA's  Office of New Drugs  ("OND") concerning the company's formal dispute resolution request. The company had appealed the decision by the FDA's  Division of Bone , Reproductive and Urological Products ("DBRUP") that concerns surrounding the in vivo adhesion properties of Twirla prevent its approval. While OND has formally denied the company's appeal, OND provided a path forward without the need to reformulate Twirla or conduct a bioequivalence study between formulations, as previously suggested by DBRUP. 

Bridgewater-based BioNJ Member   Allergan plc  announced the completion of two positive safety and tolerability studies of ubrogepant for the acute treatment of migraine. The first study (UBR-MD-04) evaluated the long-term safety and tolerability of ubrogepant (50 mg and 100 mg) compared to usual care for the acute treatment of migraine in adults for one year.The second study (3110-105-002) evaluated the hepatic safety and tolerability of ubrogepant 100 mg compared to placebo in healthy study participants over eight weeks. 

Bridgewater-based BioNJ Member   Allergan  and Medicines360 announced that the Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for  Liletta  (levonorgestrel-releasing intrauterine system) 52mg to prevent pregnancy for up to 5 years. Previously, Liletta was indicated for use up to 4 years. The expanded approval was supported by safety and efficacy data from the Phase 3 ACCESS IUS trial (N=1751) in women receiving Liletta.

East Hanover-based BioNJ Member   Novartis announced that it has entered into an agreement and plan of merger with Endocyte, a U.S.-based biopharmaceutical company focused on developing targeted therapeutics for cancer treatment. Under the terms of the agreement, Novartis would acquire all outstanding shares of Endocyte common stock for USD 24 per share. This offer values Endocyte's equity at USD 2.1 billion.

Titusville-based BioNJ Member The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved XARELTO® (rivaroxaban) to reduce the risk of major cardiovascular (CV) events, such as CV death, myocardial infarction (MI) and stroke, in people with chronic coronary or peripheral artery disease (CAD/PAD). XARELTO® is now the first and only Factor Xa inhibitor approved for patients living with these conditions.

Titusville-based BioNJ Member The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for esketamine nasal spray, a glutamate receptor modulator, for treatment-resistant depression (TRD) in adults with Major Depressive Disorder (MDD) who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.

Titusville-based BioNJ Member The Janssen Pharmaceutical Companies of Johnson & Johnson announced new data showing treatment with a single intravenous (IV) dose of STELARA® (ustekinumab) induces clinical remission and response in adults with moderate to severe ulcerative colitis (UC) who previously experienced an inadequate response or intolerance to conventional or biologic therapies. 

Titusville-based BioNJ Member The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Janssen Pharmaceuticals, Inc. has entered into an agreement with Arrowhead Pharmaceuticals, Inc. for an exclusive, worldwide license to develop and commercialize ARO-HBV, a Phase 1/2 subcutaneous, ribonucleic acid interference (RNAi) therapy candidate being investigated for the treatment of chronic hepatitis B viral infection.

The  U.S. Department of Health and Human Services'  Office of the Assistant Secretary for Preparedness and Response announced that it will expand a strategic partnership with BioNJ Member  Johnson & Johnson .The expansion will focus on the development of innovative products to combat the potentially deadly health effects of chemical, biological, radiation and nuclear threats, emerging infectious diseases and antimicrobial resistant infections.

Results from a new national, multi-stakeholder survey commissioned by  Bridgewater-based BioNJ Member  Eli Lilly and Company  reveal that metastatic breast cancer (MBC) places a significant daily strain on those living with the incurable disease. People with MBC who participated in the survey reported spending nearly half their time each week (47%) on things related to their cancer. 

BioNJ Member  Eli Lilly and Company and  Boehringer Ingelheim announced novel results based on data from the landmark EMPA-REG OUTCOME® trial were published in the journal  Circulation  which suggest that treatment with Jardiance®  positively impacts life expectancy in adults with type 2 diabetes and established cardiovascular disease . Using actuarial methods, and assuming that the demonstrated beneficial effects of Jardiance remain consistent with long-term use, Jardiance was estimated to extend life expectancy by 1 to 4.5 years on average, depending on age, when compared with placebo. 

Princeton-based BioNJ Member Evotec AG announced that the company will receive a $6M payment from Celgene following Celgene's decision to expand the collaboration to include additional cell lines. Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. The collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging Evotec's unique human induced pluripotent stem cell ("iPSC") technology platform. 

Princeton-based BioNJ Member Evotec AG and Parsippany-based BioNJ Member Ferring Pharmaceuticals announced a strategic research alliance to discover and develop new small molecule therapies to treat patients living with fertility and gynaecological conditions. Evotec will apply its drug discovery platform to design novel, safe and efficacious treatments in partnership with Ferring. The multi-target, multi-year collaboration aims to deliver small molecule pre-clinical development ("PDC") and investigational new drug ("IND") ready candidates.

Kenilworth-based BioNJ Member  Merck & Co. and  AstraZeneca  announced that they were granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for Lynparza  (olaparib) for the treatment of pancreatic cancer. Pancreatic cancer is a rare, life-threatening disease that accounts for about 3% of all cancers in the US. Due to the late onset of symptoms, patients are often diagnosed after the cancer has progressed to locally advanced or metastatic stages of the disease. Five-year survival rates remain low in the US at 8.5%.

Rutherfors-based BioNJ Member   Cancer Genetics, Inc. announced that it has signed an exclusive distribution agreement with Genecast Biotechnology to market, distribute and sell the Tissue of Origin® (TOO) Test in China. TOO is a microarray-based gene expression test that analyzes a tumor's genomic information to help identify its origin, which is valuable in classifying metastatic, poorly differentiated or undifferentiated cancers. 

Fort Lee-based BioNJ Member  Immune Pharmaceuticals, Inc.  announced that it has entered into a Securities Purchase Agreement with an institutional investor in which it has sold $5.5 million in principal amount of Senior Secured Redeemable Convertible Debentures (the "Debentures") for $2 million in cash and a $3 million promissory note to be funded upon the earlier of the effectiveness of a registration statement covering the resale of the issuable shares, or conversion of the Debentures.

Basking Ridge-based Daiichi Sankyo Company announced that it has submitted a New Drug Application (NDA) to Japan's Ministry of Health, Labor and Welfare (MHLW) for marketing approval of quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). The submission to Japan MHLW is based on the results of the pivotal randomized Phase 3 QuANTUM-R study in the U.S., EU and Asia excluding Japan, and an open-label Phase 2 study of quizartinib in Japan in patients with relapsed/refractory FLT3-ITD AML.

Basking Ridge-based Daiichi Sankyo Company announced that axicabtagene ciloleucel (formerly KTE-C19) has been granted Orphan Drug designation by the Japan Ministry of Health, Labour and Welfare (MHLW) for the treatment of diffuse large B-cell lymphoma (DLBCL), primary mediastinal (thymus) large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBL) and transformed follicular lymphoma (TFL), which are aggressive forms of non-Hodgkin lymphoma (NHL).

Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited and Astellas Pharma Inc. announced that the companies will jointly conduct a program called "JOINUS" (Joint Open INnovation of drUg repoSitioning) to discover new therapeutic drugs using drug-repositioning compound libraries. The JOINUS program will be carried out as a part of the companies' open innovation activities.

Lexicon Pharmaceuticals, Inc., with offices in Basking Ridge, and Ipsen Biopharmaceuticals Canada Inc. announced that Health Canada has approved XERMELO® (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of refractory carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in patients inadequately controlled by SSA therapy alone. This approval allows for the marketing of XERMELO by Lexicon's collaborator, Ipsen, in the above indication in Canada.

Warren-based Bellerophon Therapeutics, Inc.  provided an update on the Company's ongoing Phase 2b randomized, double-blind, placebo-controlled clinical study (iNO-PF) evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), as well as updated interim results from the Pulmonary Arterial Hypertension (PAH) Phase 3 trial, INOvation-1. 

Takeda Pharmaceuticals U.S.A., Inc. announced the presentation of new long-term efficacy real-world data analyses for Entyvio®  (vedolizumab) at ACG 2018. Studies of note include a retrospective multicentre cohort study of biologic-naïve adults with ulcerative colitis (UC) and Crohn's disease (CD), two systematic reviews and meta-analyses of real-world treatment persistence and mucosal healing and a time-trend analysis of Entyvio utilization and outcomes across the United States (U.S.). 

Parsippany-based  Teva Pharmaceutical Industries Ltd.  announced safety and tolerability results representing 25 years of data from the open-label extension study of the original U.S. pivotal trial of COPAXONE®  (glatiramer acetate injection) for the treatment of relapsing forms of multiple sclerosis (RMS). The extension study initially examined the safety of COPAXONE®  20 mg/mL daily and then also the 40 mg/mL three times weekly formulation when it became available approximately 20 years later. 

Pharmaceutical, life sciences and innovation economy companies were the biggest drivers to New Jersey's third quarter office activity, according to  CBRE's Q3 2018 office market reportNew leasing activity comprised approximately 1.8 million square feet, which was the second-highest third quarter recorded since 2012. Of this, 10 of the Top 20 leases were in the life sciences sector. In a deal arranged by CBRE, Teva Pharmaceuticals leased 345,000 square feet in Parsippany to serve as its new headquarters. This was the largest deal in the third quarter, CBRE said.

Beigene USA, a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer, has signed a long-term lease at 55 Challenger Road in Ridgefield Park Beigene USA began occupying its 13,000-plus square foot space in June.

People in the News

Kenilworth-based BioNJ Member Merck & Co.  announced  it has appointed Jim Scholefield as its new Chief Information and Digital Officer. Mr.  Scholefield will be responsible for leading the company's technology and digital strategy. He will also be a member of its Executive Committee. Prior to Merck, Mr. Scholefield was at NIKE Inc. as its Chief information officer. Before that, he was Chief Technology Officer at Coca-Cola and held leadership roles in information technology at The Northern Trust Co. and Ford.

Bedminster-based BioNJ Member  Matinas BioPharma Holdings, Inc.  announced that it has appointed industry and drug development veteran Theresa Matkovits, Ph.D. as Chief Development Officer. The company also announced that it has strengthened its manufacturing, supply chain and clinical development teams with the appointments of Frank Calamusa, CSCP and Jenel Cobb, Ph.D., PMP. 

Whippany-based Bayer AG  has named Scott Partridge, former Vice President of Global Strategy for  Monsanto , its new U.S. General Counsel. Mr.  Partridge, who has succeeded Jan Heinemann, Bayer's former General Counsel, began the role on Oct. 1. He reports directly to Philip Blake, Bayer U.S. president. Prior to Bayer, Mr. Partridge spent 27 years in private practice law and then moved on to Monsanto.

Thorofare-based  Akers Biosciences Inc. announced it has a new CEO.  Howard R. Yeaton has been appointed to CEO, effective immediately. He is replacing John J. Gormally, who resigned both as CEO and member of the board of directors. Mr. Yeaton, who has more than 30 years of senior financial and strategic business experience, was serving as a consultant to Akers since April. Before that, he was managing principal of Financial Consulting Strategies LLC. He currently serves as Director, Vice Chairman and Chairman of the Audit Committee for Stewardship Financial Corp.

Institution and Education News

The  Biospecimen Repository and Histopathology Service  shared resource at Rutgers Cancer Institute of New Jersey has received accreditation from the College of American Pathologists (CAP) based on results of a recent on-site inspection as part of the CAP's Accreditation Programs. The Biospecimen Repository and Histopathology Service at Rutgers Cancer Institute is a cancer center-managed shared resource offering biorepository and histopathology services to both internal and external investigators. 

Researchers from  Rutgers University have discovered a new system to deliver antimicrobial agents such as drugs, antiseptics or pesticides that could more effectively treat or prevent bacterial infections.  In a recent study published in the  Journal of The American Chemical Society , professor Tewodros Asefa and associate professor Jeffrey Boyd synthesized nanostructured silica particles, considered to be promising drug carriers, that contained payloads of an antimicrobial agent. The researchers found the particles were effective at killing two human bacterial pathogens.

A team of researchers - including scientists from Rutgers University - has discovered a way to identify Lyme disease weeks earlier than current tests allow. It's a development that eventually could help thousands of Garden State residents to start treatment sooner and better avoid the long-term effects of the disease. Experts from Rutgers Biomedical and Health Scientists worked with researchers from Harvard and Yale universities, federal agencies and other institutions on a technique to quickly, and more effectively, detect active Lyme disease infections. 

Rutgers New Jersey Medical School  announced the establishment of a new Addiction Medicine Fellowship. The one-year program, targeting the opioid epidemic, will offer three fellowship positions beginning in July. Applications will be accepted through Jan. 1. The medical school said in a statement that physicians accepted into the fellowship will have the opportunity to train in the evaluation and treatment of patients with substance use disorders, behavioral addictions and co-occurring psychiatric disorders.

Two summers ago, biomedical engineering students at  Rutgers University-New Brunswick  immersed themselves at  Matheny  in Peapack, New Jersey, a nonprofit organization that is home to scores of children and adults with cerebral palsy, spina bifida and other developmental disabilities. The students' goal: find ways to improve their independence and quality of life.

Fairleigh Dickinson University (FDU) announced the appointment of Dr. Dale G. Caldwell as Executive Director of the Rothman Institute of Innovation and Entrepreneurship.  Dean of FDU's Silberman College of Business Andrew Rosman said, "Caldwell's background and accomplishments make him the perfect fit to lead the Rothman Institute. His experience working with family businesses, coaching entrepreneurs and leading organizations will enable him to take the Institute to new levels of success."

MD Anderson Cancer Center at Cooper is participating in a clinical research study to determine if certain breast cancer patients who respond positively to neoadjuvant systemic therapy can be treated without surgery.  According to  Cooper University Health Care , the study is being done in conjunction with The University of Texas MD Anderson Cancer Center.

Research Day at Cooper Medical School of Rowan University (CMSRU) kicked off a new era for the school and researchers in the region.  More than 350 attendees browsed 130 poster presentations, displaying investigations ranging from basic research on cell models to clinical research on patient populations. "It's the first time our fledgling medical school is hosting this on behalf of the University," said Dean Annette Reboli, M.D.. "It coincides with the announcement by Rowan President Ali Houshmand of a $50 million investment in research at Rowan University."

Inspira Medical Center Vineland unveiled its new $34 million expansion. The expansion adds 36 new patient rooms and includes two floors totaling approximately 56,000 square feet. The project was a direct response to the community's growing demand for both emergency care and inpatient beds.

Funding News

Gov. Phil Murphy met with 25 technology and business officials and leaders from around the State at a roundtable in Newark to discuss the innovation economy. The governor spent time discussing his economic vision for the State, and the proposed venture fund -- the New Jersey Innovation Evergreen Fund -- that would raise $250 million from auctioning State tax credits, as well as another $250 million from venture capital firms, for start-ups in the State.

Nearly $50 million in financing has been provided to small and medium-sized business in 2018 through the New Jersey Economic Development Authority, leveraging more than $100 million in additional investments and 785 new full-time jobs. Click here for infographic.

The NJBAC is a state agency offering free and confidential assistance to help your business grow. As a "one-stop shop," NJBAC can help businesses of all sizes and types to manage the state's regulatory processes, boost exports, gain access to financial resources where applicable and tackle other obstacles along the way. You can download the NJBAC guide by clicking here or contact their business advocates at 1-800 JERSEY 7. 
Special Programs from Our Partners for BioNJ Members

October 24-26, 2018 | New York City

Join the NY business community to debate ethical AI, explore why tech giants are launching AI Labs in Canada, and experience cutting edge AI solutions by Canadian start-ups. The Summit includes panel discussions, fireside chats and exhibits.

October 30 - November 1, 2018 | Dallas, Texas

This national conference is the cornerstone of the HHS's congressionally mandated outreach efforts. This three-day national HHS SBIR/STTR Conference is designed to educate attendees about the America's Largest Seed Fund and how to apply for these research and development dollars. With over $1 billion dollars of annual HHS funding, this is one of the largest sources of early-stage capital for technology commercialization in the United States. The HHS's SBIR/STTR programs allow US-owned small businesses to forge academic partnerships and build productive businesses. With this funding, the partners can engage in research and development that has a strong potential to deliver products and services, including medical devices, diagnostics, digital health, biotechnology and pharmaceuticals, to improve the health of Americans.

November 2, 2018 | Newark

New Jersey Innovation Institute brings top New Jersey public and private leaders in technology and innovation to "How Innovation & Innovation Hubs Benefit Business & New Jersey." Learn how your company can become more innovative. Discover why innovation hubs attract top companies and generate high paying jobs. Topics include workforce development innovations, supply chain strategies, regional collaboration and more. Registration is free, luncheon included. Visit https://bit.ly/2A3YQwS or contact Glenda Crawford Waxter at glenda.l.crawford-waxter@njit.edu for more information.

November 5, 2018 | New York Hilton Downtown

Life Science Nation (LSN) runs the Redefining Early Stage Investments (RESI) Conference series to accelerate opportunities for you. RESI is an established and ongoing conference series that provides an international venue for early-stage life science companies across Biotech, Medtech, Diagnostics and Digital Health, to source investors from around the globe, create relationships, and potentially, secure funding. RESI NYC will expand to include the earliest stage companies from the discovery stage through venture stage: companies seeking grants, seed, angel, series A and series B funding. 

November 5-6, 2018 | New York City

The Ontario Bioscience Innovation Organization (OBIO) is bringing a delegation of high-potential Canadian health science companies to New York City on November 5th and 6th, 2018.  The Showcase features 15+ of Canada's highest-potential companies across the therapeutic, diagnostic, medical device and digital health companies. Companies are seeking seed, Series A and beyond funding rounds in 1x1 meetings. Click here to register. 

November 5-6, 2018 | New York City

The Ontario Bioscience Innovation Organization (OBIO) is bringing a delegation of high-potential Canadian health science companies to New York City on November 5th and 6th, 2018.  The Showcase features 15+ of Canada's highest-potential companies across the therapeutic, diagnostic, medical device and digital health companies. Companies are seeking seed, Series A and beyond funding rounds in 1x1 meetings. Click here to register. 

November 8, 2018 | Livingston

The Center for Medicine in the Public Interest would like to invite you to its first  Summit on 3D Printing: Exploring the Impact on Pharmaceuticals and Patient HealthThis summit brings together the leaders in 21st-century medical manufacturing from private industry, academic and government agencies with a wide range of products, patient organizations and groups dedicated to eradicating disease across the globe. RSVP to mcoluccio@cmpi.org.

November 8, 2018 | Princeton

Celebrate Princeton Innovation is an event, website and video series that honors faculty, students and staff researchers who engage in the transfer of discoveries into real-world applications through entrepreneurship. The10th anniversary is an opportunity to reflect on the truly astounding transformation of Princeton's innovation ecosystem. For more information and to register, click here

November 14-15, 2018 | Newark

The two-day program led by BIS's professional counseling staff provides an in-depth examination of the Export Administration Regulations (EAR). The program will cover the information exporters need to know to comply with U.S. export control requirements on commercial goods. We'll focus on what items and activities are subject to the EAR, steps to take to determine the export licensing requirements for your item, how to determine your export control classification number (ECCN), when you can export or reexport without applying for a license, export clearance procedures and record keeping requirements and real life examples in applying this information.  

November 15, 2018 | Hackensack Meridian Health

NJ Tech Council is developing a Mid Atlantic Immuno-Oncology Conference which will showcase I/O efforts taking place among companies and universities in the mid-Atlantic region. The goal of the conference is to give an overview of research in the region and establish a network among researchers. Questions or inquiries should be sent to Paul Frank at pfrank@njtc.org. More information including panels will be posted on the Council's website.

November 15, 2018 | Piscataway

The New Jersery Academic Drug Discovery Consortium is hosting its 2nd annual meeting at Rutgers University this year. The conference is taking place on Thursday, November 15 at the Ernest Mario School of Pharmacy. Please contact Vince Smeraglia for sponsorship opportunities at vincent.smeraglia@rutgers.edu or 732-956-6123.

November 16, 2018 | NJEDA Commercialization Center

This seminar is intended to provide entrepreneurs and small businesses with an overview of the SBIR and STTR programs with a focus on the National Institutes of Health (NIH) and 3 of its largest Institutes, The National Institute on Aging (NIA), the National Cancer Institute (NCI) and the National Institute of Allergy and Infectious Diseases NIAID). Following the morning seminar and a networking lunch, the speakers will be available for 1-to-1 appointments with attendees in the afternoon. For more information and online registration visit NJSBDC.com/sbir.

December 12, 2018 | Boston

The 13th annual New England Venture Summit, presented by youngStartup Ventures, is an industry gathering connecting venture capitalists, corporate VCs, angel investors, technology transfer professionals, senior executives of venture backed, emerging and early stage companies, university researchers, incubators and premier service providers.